胸腺肽α1在慢性阻塞性肺疾病稳定期的应用价值

目的 观察胸腺肽α1对慢性阻塞性肺疾病（COPD）稳定期患者的治疗效果.方法 60例慢性阻塞性肺疾病稳定期患者随机分为两组,两组均给予常规基础治疗,治疗组同时给予胸腺肽α1 1.6 mg皮下注射,隔日1次,连续4周,此后2次/周,持续5个月.两组患者均进行6个月随访观察,每2周门诊随访1次,进行临床病情评价,并于治疗前、治疗6个月后检查患者CD3、CD4和CD8水平.结果 治疗6个月后,治疗组患者发生急性加重次数和急性加重天数均明显低于对照组（均P＜0.01）,血清CD4及CD4/CD8比值均明显升高（均P＜0.01）.结论 胸腺肽α1通过增强患者细胞免疫功能,可有效预防慢性阻塞性肺疾病的急性加重.

Clinical application of thymosin alpha 1 in treatment of chronic obstructive pulmonary disease

Objective To observe the therapeutic effect of thymosin alpha 1 on patients with chronic obstructive pulmonary disease.Methods 60 patients with chronic obstructive pulmonary disease were divided into two groups at random.The two groups were given conventional treatment,and the treatment group was received thymosin alpha 11.6 mg hypodermic injection,1 every other day for 4 weeks,since then 2 times/week for 5 months.All patients were followed for 6 months,clinic every 2 weeks,1 follow-up,evaluation of clinical condition.In two groups,before treatment and 6 months after treatment the blood samples were collected for the measurement of the blood CD3,CD,and CD8 levels.Results In the treatment group,the number and days of patients with acute exacerbation were significantly lower in comparison with those of the control group(all P＜0.01).After treatment with thymosin alpha 1,blood CD4 and CD4/CD8 levels were significantly increased(all P＜0.01).Conclusion Thymosin alpha 1 had a good protection effect for the acute exacerbation of chronic obstructive pulmonary disease by incresing body cellular immune activity.